亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

无容量 医学 中止 肺癌 免疫疗法 肿瘤科 化疗 内科学 癌症
作者
Matteo Giaj Levra,François-Emery Cotté,Romain Corre,C. Calvet,Anne-Françoise Gaudin,John R. Penrod,V. Grumberg,B. Jouaneton,R. Jolivel,Jean‐Baptiste Assié,C. Chouaïd
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:140: 99-106 被引量:94
标识
DOI:10.1016/j.lungcan.2019.12.017
摘要

Abstract

Objectives

Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolumab and on the interest of a second course of immunotherapy after nivolumab discontinuation. The aims of this study were to describe treatment pathways following nivolumab discontinuation and to describe survival following retreatment with immunotherapy.

Materials and methods

The analysis includes all patients with NSCLC recorded in a national hospital database, starting nivolumab in 2015-2016. Nivolumab treatment was considered discontinued if ≥3 infusions were missed. Patients starting a second course of PD-1 inhibitor following nivolumab discontinuation were analysed according to the duration of their initial nivolumab treatment course.

Results

10,452 patients were included (71 % men; mean age: 63.8 ± 9.6 years; squamous histology: 44 %). Median nivolumab treatment duration was 2.8 months [IQR :1.4–6.9]. Median OS was 11.5 months [95 %CI: 11.1–11.9]; 5118 (53.4 %) patients received post nivolumab therapy lines: 1517 (29.6 %) of these received a second course of PD-1 inhibitor, either after a treatment-free interval (resumption: n=1127) or after intervening chemotherapy (rechallenge: n=390). Median OS after nivolumab discontinuation was 15.0 months [13.9–16.7] in the resumption group and 18.4 months [14.8–21.9] in the rechallenge group. Median OS was significantly longer in patients with an initial nivolumab treatment duration ≥3 months.

Conclusion

In this real-world setting, outcome after retreatment with a PD-1 inhibitor following a first course of nivolumab was significantly better in patients with a longer duration of initial nivolumab treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orixero应助老实白云采纳,获得10
4秒前
呆呆的猕猴桃完成签到 ,获得积分10
20秒前
22秒前
tian完成签到,获得积分10
25秒前
老实白云发布了新的文献求助10
28秒前
tian发布了新的文献求助30
33秒前
Yanz完成签到,获得积分10
42秒前
科研通AI5应助小嘉采纳,获得10
47秒前
鹿小新完成签到 ,获得积分0
1分钟前
深情安青应助老实白云采纳,获得10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
科研通AI2S应助科研通管家采纳,获得30
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
FashionBoy应助黄小渣采纳,获得10
1分钟前
jeff完成签到,获得积分10
1分钟前
1分钟前
小晚完成签到,获得积分10
2分钟前
2分钟前
2分钟前
小嘉发布了新的文献求助10
2分钟前
2分钟前
2分钟前
老实白云发布了新的文献求助10
2分钟前
2分钟前
量子星尘发布了新的文献求助10
2分钟前
Ruri完成签到,获得积分10
3分钟前
3分钟前
清風折柳发布了新的文献求助10
3分钟前
3分钟前
3分钟前
慕青应助清風折柳采纳,获得10
3分钟前
Sience发布了新的文献求助10
3分钟前
势临完成签到 ,获得积分10
3分钟前
Akim应助顺心蜜粉采纳,获得200
4分钟前
天天开心完成签到 ,获得积分10
4分钟前
马騳骉完成签到,获得积分10
4分钟前
量子星尘发布了新的文献求助150
4分钟前
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976649
求助须知:如何正确求助?哪些是违规求助? 3520749
关于积分的说明 11204708
捐赠科研通 3257497
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629